NDA 201373 · Chattem Sanofi
Children'S Allegra Hives
Fexofenadine Hydrochloride · Oral
Last checked: Nov 19, 2026Latest source record: Dec 27, 2022 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations
First approved
2011
Jan 24, 2011
Approved uses
1
Original approval plus efficacy supplements
Registered trials
99
15 Phase 3, 7 recruiting
FAERS reports
9,324
5,607 serious, 544 with death reported
AI brief across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.
What it is approved for
From the label in effect May 1, 2026.
Uses reduces hives and relieves itching due to hives (urticaria). This product will not prevent hives or an allergic skin reaction from occurring.
Therapeutic areas: Infectious disease and vaccines
Approval history
Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.
2 products under this application
- CHILDREN'S ALLEGRA HIVES · FEXOFENADINE HYDROCHLORIDE 30MG/5ML **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** · SUSPENSION, ORAL · Discontinued
- CHILDREN'S ALLEGRA ALLERGY · FEXOFENADINE HYDROCHLORIDE 30MG/5ML · SUSPENSION, ORAL · Over-the-counter
Clinical trials
Interventional ClinicalTrials.gov studies with "Fexofenadine" as an intervention, any sponsor and status, largest first.
- The Impact of Fexofenadine Hydrochloride on the Prognosis of Patients Post-Acute Myocardial InfarctionPivotal-lookingRecruiting
Second Affiliated Hospital, Zhejiang University, School of MedicineAcademic, hospital or other
NCT07381803 · 2,804 participants (planned) · Start Jan 27, 2025 · Primary completion Dec 2026
Drug: Fexofenadine 60 Mg Oral Tablet; Placebo · For: Zhejiang University
Sites: Hangzhou, China
- Long-Term Safety Performance of Fexofenadine in AsthmaPivotal-lookingCompleted
SanofiSanofi (SNY)
NCT00045955 · 1,200 participants (planned) · Start Feb 2002 · Primary completion Nov 2003
Drug: Fexofenadine, Comparator = Montelukast · For: Asthma
Sites: Bridgewater, New Jersey
SanofiSanofi (SNY)
NCT00637611 · 1,010 participants · Start Feb 2003
Drug: Fexofenadine HCl · For: Seasonal Allergic Rhinitis
Sites: Bridgewater, New Jersey
- Efficacy and Safety of Fexofenadine in Mild to Moderate Persistent AsthmaPivotal-lookingCompleted
SanofiSanofi (SNY)
NCT00044824 · 1,000 participants (planned) · Start Feb 2002 · Primary completion Oct 2003
Drug: Fexofenadine · For: Asthma
Sites: Bridgewater, New Jersey; Costa Rica, Costa Rica; Guatemala City, Guatemala · 7 sites in all
- Efficacy and Safety of Fexofenadine in Mild to Moderate Persistent AsthmaPivotal-lookingCompleted
SanofiSanofi (SNY)
NCT00044811 · 1,000 participants (planned) · Start Mar 2002 · Primary completion Oct 2003
Drug: Fexofenadine · For: Asthma
Sites: Bridgewater, New Jersey; Costa Rica, Costa Rica; Guatemala City, Guatemala · 7 sites in all
- Fluticasone Furoate Nasal Spray Versus Oral FexofenadinePivotal-lookingCompleted
GlaxoSmithKlineGSK (GSK)
NCT00435461 · 1,000 participants · Start Dec 20, 2006 · Primary completion Feb 1, 2007
Drug: Fluticasone furoate and fexofenadine · For: Rhinitis, Allergic, Seasonal
Sites: Austin, Texas; Kerrville, Texas; New Braunfels, Texas · 6 sites in all
- Efficacy and Safety of Desloratadine vs. Fexofenadine 180 mg. vs. Placebo for Treating Seasonal Allergic Rhinitis (SAR) (Study P04054)Pivotal-lookingCompleted
Organon and CoIndustry
NCT00783146 · 728 participants · Start Aug 1, 2004 · Primary completion Oct 1, 2004
Drug: desloratadine; fexofenadine and 1 more · For: Seasonal Allergic Rhinitis
- Efficacy and Safety of Desloratadine vs. Fexofenadine 180 mg. vs. Placebo for Treating Seasonal Allergic Rhinitis (SAR)(Study P04053)(COMPLETED)Pivotal-lookingCompleted
Organon and CoIndustry
NCT00783211 · 722 participants · Start Aug 1, 2004 · Primary completion Oct 1, 2004
Drug: desloratadine; fexofenadine and 1 more · For: Seasonal Allergic Rhinitis
Most reported adverse reactions
FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.
- drug ineffective868
- nausea483
- diarrhoea456
- headache456
- fatigue453
- dizziness406
- pruritus405
- dyspnoea385
- product quality issue359
- rash350
- pain286
- malaise279
FAERS reports by year
By the date FDA received the report.
View as table
| Year | Reports |
|---|---|
| 2004 | 215 |
| 2005 | 206 |
| 2006 | 77 |
| 2007 | 61 |
| 2008 | 82 |
| 2009 | 88 |
| 2010 | 265 |
| 2011 | 239 |
| 2012 | 206 |
| 2013 | 191 |
| 2014 | 205 |
| 2015 | 383 |
| 2016 | 532 |
| 2017 | 520 |
| 2018 | 535 |
| 2019 | 674 |
| 2020 | 693 |
| 2021 | 677 |
| 2022 | 664 |
| 2023 | 622 |
| 2024 | 653 |
| 2025 | 824 |
| 2026 | 711 |
Recalls
0 FDA enforcement reports for this application.
No recalls on record for this application.
Shortages
FDA's drug shortage list.
Not on FDA's shortage list.
Medicare spending
CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.
Not found under this brand name in Medicare's Part D or Part B Spending by Drug data. CMS lists some drugs under the generic name only.
Published evidence
PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.
- Interactions between herbal medicines and prescribed drugs: an updated systematic review.
Izzo AA, Ernst E · Drugs 2009 · Systematic Review
- The efficacy and safety of H1-antihistamine versus Montelukast for allergic rhinitis: A systematic review and meta-analysis.
Wei C · Biomed Pharmacother 2016 · Comparative Study, Meta-Analysis
- The incidence of sleepiness in newer-generation antihistamine users: a systematic review and network meta-analysis.
Leelakanok N, Pongpun A, Sapapsap B, et al. · Eur J Clin Pharmacol 2026 · Systematic Review, Network Meta-Analysis
- A systematic review of randomized controlled trials for prevention or treatment of atopic dermatitis in dogs: 2008-2011 update.
Olivry T, Bizikova P · Vet Dermatol 2013 · Systematic Review
- Why fexofenadine is considered as a truly non-sedating antihistamine with no brain penetration: a systematic review.
Ansotegui IJ, Bousquet J, Canonica GW, et al. · Curr Med Res Opin 2024 · Systematic Review
- Comparison of efficacy, safety, and cost-effectiveness of montelukast-levocetirizine and montelukast-fexofenadine in patients of allergic rhinitis: A randomized, double-blind clinical trial.
Mahatme MS, Dakhale GN, Tadke K, et al. · Indian J Pharmacol 2016 · Comparative Study, Randomized Controlled Trial
Sponsor: Chattem Sanofi · Also marketed as Children'S Allegra Allergy
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.